載入中
Quoin Pharmaceuticals, Ltd. operates as a specialized pharmaceutical firm, concentrating its efforts on devising therapeutic solutions for rare and orphan medical conditions. Its flagship offering, QRX003, is a topical lotion specifically formulated to address Netherton Syndrome. Furthermore, the company is advancing QRX004 for the management of dystrophic epidermolysis bullosa, alongside QRX006, a prospective therapy for an additional rare dermatological ailment. The organization maintains its operational base in Ashburn, Virginia.
前收盤價
US$4.70
−US$0.02 · -0.42%
盤前
US$4.42
−US$0.28 · -5.96%
10月8日 上午4:10 ET
盤中時間採用ET。市場資料可能有所延遲。
Quoin Pharmaceuticals, Ltd. operates as a specialized pharmaceutical firm, concentrating its efforts on devising therapeutic solutions for rare and orphan medical conditions. Its flagship offering, QRX003, is a topical lotion specifically formulated to address Netherton Syndrome. Furthermore, the company is advancing QRX004 for the management of dystrophic epidermolysis bullosa, alongside QRX006, a prospective therapy for an additional rare dermatological ailment. The organization maintains its operational base in Ashburn, Virginia.
日內區間
目前US$4.70
52週區間
目前US$4.70
盤中時間採用ET。市場資料可能有所延遲。
GoAI 評分
賣出
估值
43
合理估值
情緒
58
多空交錯
風險
74
高風險
動能
19
強勢下行
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
Quoin Pharmaceuticals, Ltd. operates as a specialized pharmaceutical firm, concentrating its efforts on devising therapeutic solutions for rare and orphan medical conditions. Its flagship offering, QRX003, is a topical lotion specifically formulated to address Netherton Syndrome. Furthermore, the company is advancing QRX004 for the management of dystrophic epidermolysis bullosa, alongside QRX006, a prospective therapy for an additional rare dermatological ailment. The organization maintains its operational base in Ashburn, Virginia.
日內區間
目前US$4.70
52週區間
目前US$4.70
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 研究與開發 | 980.28萬 USD | 360.26萬 USD | 330.8萬 USD | 267.28萬 USD | 156.29萬 USD |
| 銷售、一般及管理費用 | 648.79萬 USD | 592.58萬 USD | 607.05萬 USD | 658.49萬 USD | 449.99萬 USD |
| 營業費用 | 1629.07萬 USD | 952.85萬 USD | 937.85萬 USD | 925.77萬 USD | 606.29萬 USD |
| 利息收入 | 48.21萬 USD | 55.85萬 USD | 69.46萬 USD | 9.57萬 USD | — |
| 利息支出 | — | — | — | 71.41萬 USD | 109.04萬 USD |
| 折舊和攤銷 | 10萬 USD | 10萬 USD | 10.37萬 USD | 10.4萬 USD | 10.4萬 USD |
| 營業利益 | −1629.07萬 USD | −952.85萬 USD | −937.85萬 USD | −925.77萬 USD | −606.29萬 USD |
| 淨利 | −1580.47萬 USD | −896.25萬 USD | −868.66萬 USD | −938.15萬 USD | −2146.26萬 USD |
公司資料更新於 2026年10月8日。
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$20.00
上漲空間 325.53%評級樣本有限，僅4項
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
